A5132 TRIAL TO EVALUATE INTERLEUKIN-2 (IL-2) POTENT ANTIRETROVIRAL THERAPY

A5132 评估白细胞介素 2 (IL-2) 有效抗逆转录病毒治疗的试验

• 批准号: 7605184
• 负责人: THOMAS C MERIGAN
• 金额: $ 0.38万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-15 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605184
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Immune response; Institution; Interleukin-2; Interruption; Label; Randomized Controlled Clinical Trials; Rate; Research; Research Personnel; Resources; Source; United States National Institutes of Health; antiretroviral therapy

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5132 is an exploratory, open-label, randomized trial to evaluate the ability of IL-2 to enhance HIV-specific immune responses and influence the rate of virologic rebound following potent antiretroviral therapy (ART) interruptions.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 A5132是一项探索性、开放标签、随机试验，旨在评估IL-2增强HIV特异性免疫应答的能力，并影响强效抗逆转录病毒治疗（ART）中断后的病毒学反弹率。